Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.43 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL1279705 | 0.97 | TBXA2R (0.44) | CNR1TRPV4TRPM8KMT2AALDH1A1 | |
| SCHEMBL1279160 | 0.96 | TBXA2R (0.46) | CNR1TRPV4TRPM8KMT2AALDH1A1 | |
| Phosphoric Acid SCHEMBL1279187 | 0.95 | CNR1 (0.43) | CNR1TRPV4TRPM8KMT2AALDH1A1 | |
| SCHEMBL1279808 | 0.88 | MAPK1 (0.46) | KMT2AALDH1A1TSHRMAPK1HSD17B10 | |
| SCHEMBL692824 | 0.88 | ALDH1A1 (0.45) | CNR1TRPV4TRPM8KMT2AALDH1A1 | |
| Bromide SCHEMBL1279110 | 0.88 | MAPK1 (0.45) | KMT2AALDH1A1TSHRMAPK1HSD17B10 | |
| Hydrochloric Acid SCHEMBL1279664 | 0.88 | MAPK1 (0.45) | KMT2AALDH1A1TSHRMAPK1HSD17B10 | |
| SCHEMBL2821873 | 0.86 | HRH1 (0.42) | CNR1TRPV4TRPM8KMT2AALDH1A1 | |
| SCHEMBL13413623 | 0.86 | ALDH1A1 (0.58) | TRPV4TRPM8KMT2AALDH1A1TSHR | |
| SCHEMBL13679842 | 0.86 | ALDH1A1 (0.58) | TRPV4TRPM8KMT2AALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2627635-A1 | SALTS OF ARYLSULFONAMIDE CCR3 ANTAGONISTS | Axikin Pharmaceuticals, Inc. (US) | 2013-08-21 | — | — | EP | claimed |
| WO-2012051090-A1 | SALTS OF ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2012-04-19 | — | — | WO | claimed |
| US-20120088769-A1 | SALTS OF ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2012-04-12 | — | — | US | claimed |
| EP-2627635-A1 | SALTS OF ARYLSULFONAMIDE CCR3 ANTAGONISTS | Axikin Pharmaceuticals, Inc. (US) | 2013-08-21 | — | — | EP | disclosed |
| WO-2012051090-A1 | SALTS OF ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2012-04-19 | — | — | WO | disclosed |
| US-20120088769-A1 | SALTS OF ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088769-A1 | SALTS OF ARYLSULFONAMIDE CCR3 ANTAGONISTS | CCR3, CCR1, CCR4 | CNR1 52/4885TRPV4 762/4885TRPM8 1008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.